nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.12.2010 | Original Paper

Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer

verfasst von: Gudrun Knechtel, Günter Hofmann, Armin Gerger, Wilfried Renner, Tanja Langsenlehner, Joanna Szkandera, Gerald Wolf, Hellmut Samonigg, Peter Krippl, Uwe Langsenlehner

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Women with breast cancer that initially involves local lymph nodes have a higher risk for local recurrence or developing metastases. Recent data suggest that germline polymorphism is a significant, previously unrecognized factor in breast cancer progression and metastasis. We assessed the influence of 16 selected common germline polymorphisms in disease-free survival and overall survival among 216 women diagnosed with lymph node-positive breast cancer.

Results

The rare allele of FAS 1377G>A was significantly associated with prolonged disease-free survival (P = 0.012, risk ratio of recurrence (RR) = 0.557, 95% confidence interval (CI) = 0.353–0.878) in univariate analysis. After adjusting for known breast cancer prognostic factors the association remained significant (P = 0.050, RR = 0.500, CI = 0.309–0.809). In overall survival analysis we found a significant association of the FAS 1377G>A (P = 0.040, RR = 0.451, CI = 0.496–1.188) and IL10 592C>A polymorphisms (P = 0.020, RR = 1.707, CI = 1.087–2.680) in the univariate Cox regression. The effect remained statistically significant in the multivariate analysis for the IL10 592C>A polymorphism (P = 0.013, RR 1.841, CI 1.140–2.973). No association was found for MTHFR 677C>T, VEGF 936C>T, CCND1 870G>A, TGFB1 29T>C, FASLG 844C>T, FAS 670A>G, GPB3 825C>T, ITGA2 807C>T, ITGA2 1648G>A, ITGB3 176T>C, MMP1 -1607 1G/2G, MMP3 5A/6A, PTGS2 8473T>C, IL10 592C>A and SULT1A1 638G>A polymorphisms and disease-free survival or overall survival.

Conclusions

Our data suggest that the FAS 1377G>A and IL10 592C>A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.

Balasubramanian SP, Azmy IA, Higham SE, Wilson AG, Cross SS, Cox A, Brown NJ, Reed MW (2006) Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer 6:188CrossRefPubMed

Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME (2004) CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 23:3175–3185CrossRefPubMed

Campbell IG, Baxter SW, Eccles DM, Choong DY (2002) Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer. Breast Cancer Res 4:R14CrossRefPubMed

Clar H, Langsenlehner U, Krippl P, Renner W, Leithner A, Gruber G, Hofmann G, Yazdani-Biuki B, Langsenlehner T, Windhager R (2008) A polymorphism in the G protein beta3-subunit gene is associated with bone metastasis risk in breast cancer patients. Breast Cancer Res Treat 111:449–452CrossRefPubMed

Crew KD, Gammon MD, Terry MB, Zhang FF, Agrawal M, Eng SM, Sagiv SK, Teitelbaum SL, Neugut AI, Santella RM (2007) Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis 28:2548–2551CrossRefPubMed

Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O’Garra A (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147:3815–3822PubMed

Gerger A, Langsenlehner U, Renner W, Weitzer W, Eder T, Yazdani-Biuki B, Hofmann G, Samonigg H, Krippl P (2007) A multigenetic approach to predict breast cancer risk. Breast Cancer Res Treat 104:159–164CrossRefPubMed

Gerger A, Renner W, Langsenlehner T, Hofmann G, Knechtel G, Szkandera J, Samonigg H, Krippl P, Langsenlehner U (2010) Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Res Treat 119:701–705CrossRefPubMed

Gormus U, Ergen A, Yaylim-Eraltan I, Yilmaz H, Turna A, Bozkurt N, Isbir T (2007) Fas-1377 A/G polymorphism in lung cancer. In Vivo 21:663–666PubMed

Holliday DL, Hughes S, Shaw JA, Walker RA, Jones JL (2007) Intrinsic gene characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion. Breast Cancer Res 9:67CrossRef

Honig SF (1996) Treatment of metastatic disease: hormonal therapy and chemotherapy. In: Harris JR, Lippman M, Morrow M (eds) Diseases of the breast. Lippincott-Raven Publishers, Philadelphia, pp 669–734

Howell WM, Rose-Zerilli MJ (2006) Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer 5:143–149CrossRefPubMed

Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, Stevens VL, Patel AV, Thun MJ, Calle EE (2006) Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the cancer prevention study II cohort. Breast Cancer Res 8:R22CrossRefPubMed

Kang S, Dong SM, Seo SS, Kim JW, Park SY (2008) FAS -1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet 180:1–5CrossRefPubMed

Kim JG, Chae YS, Sohn SK, Cho YY, Moon JH, Park JY, Jeon SW, Lee IT, Choi GS, Jun SH (2008) Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res 14:62–66CrossRefPubMed

Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Bahadori B, Samonigg H (2003) The L10P polymorphism of the transforming growth factor-beta 1 gene is not associated with breast cancer risk. Cancer Lett 201:181–184CrossRefPubMed

Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Samonigg H (2004) The 825C>T polymorphism of the G-protein beta-3 subunit gene (GNB3) and breast cancer. Cancer Lett 206:59–62CrossRefPubMed

Langsenlehner U, Krippl P, Renner W, Yazdani-Biuki B, Eder T, Wolf G, Wascher TC, Paulweber B, Weitzer W, Samonigg H (2004) Genetic variants of the sulfotransferase 1A1 and breast cancer risk. Breast Cancer Res Treat 87:19–22CrossRefPubMed

Langsenlehner U, Yazdani-Biuki B, Eder T, Renner W, Wascher TC, Paulweber B, Weitzer W, Samonigg H, Krippl P (2006) The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk. Clin Cancer Res 12:1392–1394CrossRefPubMed

Le Marchand L, Haiman CA, van den Berg D, Wilkens LR, Kolonel LN, Henderson BE (2004) T29C polymorphism in the transforming growth factor beta1 gene and postmenopausal breast cancer risk: the Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev 13:412–415PubMed

Lee JK, Sayers TJ, Back TC, Wigginton JM, Wiltrout RH (2003) Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer. Apoptosis 8:151–160CrossRefPubMed

Lei H, Zaloudik J, Vorechovsky L (2002) Lack of association of the -1171 (5A) allele of the MMP3 promoter with breast cancer. Clin Chem 48:798–799PubMed

Lifsted T, Le Voyer T, Williams M, Muller W, Klein-Szanto A, Buetow KH, Hunter KW (1998) Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer 77:640–644CrossRefPubMed

Linnebank M, Semmler A, Moskau S, Smulders Y, Blom H, Simon M (2008) The methylenetetrahydrofolate reductase (MTHFR) variant c.677C>T (A222 V) influences overall survival of patients with glioblastoma multiforme. Neuro Oncol 10:548–552CrossRefPubMed

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235CrossRefPubMed

Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M (2004) The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 15:61–76CrossRefPubMed

Müschen M, Warskulat U, Beckmann MW (2000) Defining CD95 as a tumor suppressor gene. J Mol Med 78:312–325CrossRefPubMed

Nagata S, Golstein P (1995) The Fas death factor. Science 267:1449–1456CrossRefPubMed

Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. CA Cancer J Clin 55:74–108CrossRefPubMed

Qui LX, Shi J, Yuan H, Jiang X, Xue K, Pan HF, Li J, Zheng MH (2009) FAS-1377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls. Hum Gen 125:431–435CrossRef

Shinohara H, Yagita H, Ikawa Y, Oyaizu N (2000) Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation. Cancer Res 60:1766–1772PubMed

Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, Skibola CF, Smith MT, Morgan GJ (2003) Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 63:4327–4330PubMed

Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D (2004) Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96:1030–1036CrossRefPubMed

Takayama H, Takakuwa T, Tsujimoto Y, Nonomura N, Okuyama A, Aozasa K (2002) Analysis of Fas gene mutations on laser capture microdissected specimens from renal cell carcinoma. Jpn J Cancer Res 93:1201–1206PubMed

Ter-Minassian M, Zhai R, Asomaning K, Su L, Zhou W, Liu G, Heist RS, Lynch TJ, Wain JC, Lin X, De Vivo I, Christiani DC (2008) Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis 29:2147–2152CrossRefPubMed

Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24:1–8PubMed

Wesche-Soldato DE, Swan RZ, Chung CS, Ayala A (2007) The apoptotic pathway as a therapeutic target in sepsis. Curr Drug Targets 8:493–500CrossRefPubMed

Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC (2004) Expansion of myeloid immune suppressor Gr + CD11b + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409–421CrossRefPubMed

Yaylim-Eraltan I, Ergen A, Görmüs U, Arikan S, Küçücük S, Sahin O, Yigit N, Yildiz Y, Isbir T (2009) Breast cancer and cyclin D1 gene polymorphism in Turkish women. In Vivo 23:767–772PubMed

Zhang Z, Wang LE, Sturgis EM, El-Naggar AK, Hong WK, Amos CI, Spitz MR, Wei Q (2006) Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 12:5596–5602CrossRefPubMed

Zhang B, Sun T, Xue L, Han X, Zhang B, Lu N, Shi Y, Tan W, Zhou Y, Zhao D, Zhang X, Guo Y, Lin D (2007) Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 28:1067–1073CrossRefPubMed

Zhang Y, Liu Q, Zhang M, Yu Y, Liu X, Cao X (2009) Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J Immunol 182:3801–3808CrossRefPubMed

Titel: Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer
verfasst von: Gudrun Knechtel
Günter Hofmann
Armin Gerger
Wilfried Renner
Tanja Langsenlehner
Joanna Szkandera
Gerald Wolf
Hellmut Samonigg
Peter Krippl
Uwe Langsenlehner
Publikationsdatum: 01.12.2010
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 12/2010
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-010-0839-2

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer